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Mitochondrial phosphate carrieryde, mitochondria possess two distinct persona. Under normal physiological
conditions they synthesise ATP to meet the energy needs of the beating heart. Here calcium acts as a signal to
balance the rate of ATP production with ATP demand. However, when the heart is overloaded with calcium,
especially when this is accompanied by oxidative stress, mitochondria embrace their darker side, and induce
necrotic cell death of the myocytes. This happens acutely in reperfusion injury and chronically in congestive
heart failure. Here calcium overload, adenine nucleotide depletion and oxidative stress combine forces to
induce the opening of a non-speciﬁc pore in the mitochondrial membrane, known as the mitochondrial
permeability transition pore (mPTP). The molecular nature of the mPTP remains controversial but current
evidence implicates a matrix protein, cyclophilin-D (CyP-D) and two inner membrane proteins, the adenine
nucleotide translocase (ANT) and the phosphate carrier (PiC). Inhibition of mPTP opening can be achieved
with inhibitors of each component, but targeting CyP-D with cyclosporin A (CsA) and its non-
immunosuppressive analogues is the best described. In animal models, inhibition of mPTP opening by
either CsA or genetic ablation of CyP-D provides strong protection from both reperfusion injury and
congestive heart failure. This conﬁrms the mPTP as a promising drug target in human cardiovascular disease.
Indeed, the ﬁrst clinical trials have shown CsA treatment improves recovery after treatment of a coronary
thrombosis with angioplasty.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
In the healthy heart changes in mitochondrial calcium concentra-
tions ([Ca2+]m) play a critical role in regulating oxidative phosphor-
ylation and enable the supply of ATP to match ATP demand in
response to increased work load. This involves the operation of
speciﬁc calcium transport pathways [1,2] that relay the beat by beat
increases in cytosolic [Ca2+] into the mitochondrial matrix [3,4],
where they activate mitochondrial dehydrogenases [5–7] to provide
an increased supply of NADH to fuel the respiratory chain. When the
heart works harder, the greater frequency and magnitude of the
calcium transients produces greater activation of the dehydrogenases
thus stimulating ATP production [8]. Additional Ca2+-dependent
mechanisms may also be involved including stimulation of the proton
translocating ATPase and activation of the respiratory chain bye; BKA, bongkrekic acid; CAT,
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ll rights reserved.increases in matrix volume [9–11]. Taken together, these mechanisms
provide an explanation of how the ATP and creatine phosphate
concentrations of the heart are maintained as workload increases
[8,11]. However, there are pathological conditions in which cytosolic
[Ca2+] becomes excessively high. This can lead to mitochondrial
calcium overload with an increased risk of damage to the mitochon-
dria through the opening of the mitochondrial permeability transition
pore (mPTP).
In this review we will ﬁrst introduce the mPTP, describing the
consequences of its opening and what is known of its molecular
mechanism and regulation (Section 2 ‘Themitochondrial permeability
transition pore’). In Section 3 ‘mPTP opening is a critical factor in
reperfusion injury and heart failure’ we will describe how calcium
overload and oxidative stress occur during ischaemia (loss of blood
ﬂow) and subsequent reperfusion, and how this can lead to mPTP
opening and damage to the heart (reperfusion injury). This has major
clinical implications in cardiac surgery or following a coronary
thrombosis (a blood clot in the coronary arteries supplying the heart
with blood that leads to a heart attack) and subsequent treatment
(reperfusion). In Section 4 ‘Inhibition of the mPTP protects hearts
against ischaemia reperfusion injury’we review how inhibition of the
mPTP can protect the heart from such reperfusion injury and thus
offers an effective therapeutic strategy for cardioprotection. Finally, in
Section 5 ‘Heart failure in cardiac hypertrophy may be ameliorated by
inhibition of the mPTP’ we describe how dysregulation of calcium
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hypertrophy (enlarged heart) that can develop into chronic hyperten-
sion (high blood pressure). The mPTP has also been implicated in the
development of this disease and here too its inhibition may offer a
promising approach to reducing disease progression.
2. The mitochondrial permeability transition pore
The mPTP is a non-selective pore, permeable to any molecule of
less than 1.5 kDa, that opens in the mitochondrial inner membrane
under conditions of very high (pathological) [Ca2+]m. However, an
increase in [Ca2+]m alone is relatively ineffective at triggering pore
opening, but the sensitivity to [Ca2+]m can be greatly enhanced by
adenine nucleotide depletion, high [Pi] and most importantly,
oxidative stress [12–15]. Such conditions prevail during ischaemia
and reperfusion and initiate mPTP opening under such conditions as
will be described below (Section 3 ‘mPTP opening is a critical factor in
reperfusion injury and heart failure’). There are two consequences of
mPTP opening that can play an important role in cell death. The ﬁrst of
these is uncoupling which occurs because the increased permeability
to protons leads to dissipation of the two components of the proton
motive force (pmf), the pH gradient and the membrane potential. In
the absence of a pmf, mitochondria cannot synthesise ATP via
oxidative phosphorylation. Indeed the ATPase goes into reverse and
starts to breakdown the ATP produced by glycolysis and any
remaining competent mitochondria. As a result, myocytes in which
a signiﬁcant number of mitochondria have undergone the mPTP
cannot maintain their ATP levels and the resulting disruption of
metabolism and ionic homeostasis leads to necrotic cell death
[13,14,16].
The second consequence of mPTP opening,mitochondrial swelling,
occurs because the increased permeability of the inner mitochondrial
membrane to small molecules causes equilibration of low molecular
weight osmolytes whilst retaining proteins in their respective
compartments. Since the matrix protein concentration is very high,
it exerts a colloidal osmotic pressure leading to swelling of the matrix
compartment. Swelling can occur without compromising the integrity
of inner membrane because the cristae unfold, but as the matrix
expands it exerts pressure on the outer membrane that eventually
ruptures. This will cause release of cytochrome c and other pro-
apoptotic proteins and has the potential to lead to apoptotic cell death
[17–21]. However, only if the pores close again sufﬁciently to maintain
ATP levels will apoptotic death predominate over necrotic cell death
[13]. Fig. 1 provides an overview of the consequences of mPTP opening
and key features of the proposed molecular mechanism described in
Section 2.1 ‘The molecular composition of the mPTP’ below.Fig. 1. An overview of the proposed mechanism of the mitochondrial permeability transitio
mitochondrial permeability transition pore’ of the text.2.1. The molecular composition of the mPTP
The phenomenon of the permeability transition was ﬁrst recog-
nised more than 40 years ago as the massive swelling of mitochondria
that accompanies calcium overload. It was originally thought to
represent a non-speciﬁc permeabilisation of the mitochondrial inner
membrane through activation of Ca-sensitive phospholipases [22–24].
However, pioneering studies by Haworth and Hunter [25,26] and later
by Crompton et al. [27] demonstrated that the pore was likely to be a
unique molecular identity with a molecular cut-off of about 1.5 kDa.
Its opening is triggered by calcium and can be rapidly closed again by
calcium chelation. Work from this laboratory and that of many others
have sought to elucidate the molecular mechanism of the mPTP
although its exact composition remains uncertain [12,14,15,28].
However, the most recent data provides the strongest evidence for
an involvement of three proteins: a mitochondrial peptidyl-prolyl
cis–trans isomerase known as cyclophilin-D, the adenine nucleotide
translocase (ANT) and the mitochondrial phosphate carrier (PiC)
[28]. Since these components act as potential targets for mPTP and
hence cardioprotection, evidence for their involvement will be
summarised brieﬂy.
2.1.1. A role for cyclophilin-D (CyP-D)
In 1988 Crompton et al. reported that cyclosporin A acts as a potent
inhibitor of mPTP opening [29]. Subsequent work in this laboratory
demonstrated that inhibition of pore opening by CsA and its analogues
was mediated by inhibition of a matrix peptidyl-prolyl cis–trans
isomerase (PPIase) that was later puriﬁed and showed to be
cyclophilin-D (CyP-D) [30–32]. The potency of a range of CsA
analogues as inhibitors of the mPTP matched their potency as
inhibitors of the PPIase activity of CyP-D [33] and a similar correlation
was found with an unrelated drug, sanglifehrin A (SfA) [34]. CyP-D is
an 18 kDa matrix protein that is encoded by the nuclear gene PPIF and
is synthesised with a targeting sequence that is cleaved following
translocation into the matrix [31,35]. Final proof of its role in mPTP
opening was provided recently using CyP-D knockout mice. Mito-
chondria from these mice were found to be highly resistant to
calcium-induced mPTP opening and behaved the same as mitochon-
dria from wild-type mice treated with CsA [36–39]. The inhibitory
effect of CsA and SfA on mPTP opening is associated with a reduction
in the calcium sensitivity of pore opening rather than a total blockade.
Thus, in the presence of CsA or SfA [34,40], or in mitochondria from
CyP-D knockout mice [36], pore opening can still be induced at high
calcium loading. These data imply that mPTP opening involves a
conformational change in a membrane protein that is triggered by
calcium and facilitated by (rather than totally dependent on) CyP-D.n pore and the consequences of its opening. Further details are given in Section 2 ‘The
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should be noted that He and Lemasters [41] have suggested that there
may not be a single unique membrane protein involved. Rather, they
propose that the mPTP forms as a result of the aggregation of
misfolded integral membrane proteins that have been damaged by
oxidant and other stresses. In their model, CyP-D is suggested to block
conductance through these protein aggregates, but when protein
clusters exceed the CyP-D available, unregulated pore opening occurs
that is stimulated by calcium and inhibited by CsA binding to CyP-D.
The apparent involvement of the ANT and PiC in pore formation (see
below) could be explained by the abundance of these proteins in the
inner mitochondrial membrane and their susceptibility to oxidative
damage. However, the ability of different ligands of the ANT and PiC to
either activate or inhibit mPTP opening (see below) is not readily
reconcilable with this model.
2.1.2. A role for the adenine nucleotide translocase (ANT)
Work from several laboratories, including our own, has demon-
strated that opening of the mPTP can be inhibited by ATP, ADP and
bongkrekic acid (BKA), an inhibitor of the ANT, all of which decreased
the sensitivity of pore opening to [Ca2+] [26,30,42]. Conversely,
activation is achieved by adenine nucleotide depletion or another
inhibitor of the ANT, carboxyatractyloside (CAT) that sensitise the
pore to [Ca2+] [40]. Since CAT and BKA trap the ANT in opposite
conformations [43] these data implicate the ANT in the formation or
regulation of the mPTP. Furthermore, the speciﬁcity for inhibition of
themPTP by nucleotidesmatches their ability to be transported by the
ANT [40]. In the light of these data we proposed [30,33] and
subsequently reﬁned [24,44] a model for the mPTP in which CyP-D
binds to the ANT and then, when triggered by calcium, causes it to
undergo a conformational change to induce pore formation. Since its
original proposal additional evidence has accumulated in support of
this model. Thus the ANT was found to bind to a glutathione-CyP-D
column [45,46] and binding was increased by oxidative stress
[45,47,48]. Oxidative stress was shown to further sensitise the mPTP
to [Ca2+] by antagonising adenine nucleotide binding to the ANT
through cross-linking of two thiol groups on the matrix surface of the
ANT close to the adenine nucleotide binding site [48]. Furthermore,
Brustovetsky and Klingenberg demonstrated that the puriﬁed and
reconstituted adenine nucleotide translocase of Neurospora crassa
forms non-speciﬁc channels at high calcium concentrations [49] and
that the opening probability of these channels is increased at high
membrane potential by oxidative stress and the presence of
cyclophilin [50].
Despite this extensive evidence for an important role for the ANT
in mPTP formation, an essential role has been ruled out since mouse
liver mitochondria lacking ANT1 and ANT2 still exhibit a CsA-sensitive
permeability transition [51]. However, the mPTP in these mitochon-
dria is insensitive to ligands of the ANT and requires much higher
[Ca2+] to open. Although there are some criticisms that can be leveled
against these studies [28,52] they do imply that another protein must
play an important role in mPTP formation. Recent studies from this
laboratory have suggested that the mitochondrial phosphate carrier
(PiC) may be that protein [28,53].
2.1.3. A role for the mitochondrial phosphate carrier
Phosphate has been recognised as an activator of the permeability
transition for more than 20 years and our recent studies have
suggested that this effect may involve the PiC [53]. We had
previously shown that phenylarsine oxide (PAO) could mimic the
activation of the mPTP by oxidative stress and that this correlated
with modiﬁcation of two matrix cysteine groups on the ANT [24,40].
We were also able to show that immobilised PAO was able to pull
down the ANT from detergent-solubilised inner mitochondrial
membranes and that this could be prevented by pre-treatment of
the mitochondria with CAT or BKA [40,53]. However, PAO could stillactivate mPTP opening in CAT- or BKA-treated mitochondria which
is not consistent with this effect being purely mediated through
PAO-binding to the ANT [53]. Thus we investigated whether other
inner membrane proteins from CAT-treated mitochondria bound to
a PAO-afﬁnity matrix. We identiﬁed four such proteins, one of which
was the PiC [53]. Its binding was unaffected by CAT- or BKA-
treatment but could be abolished by treatment with the ubiquinone
analogues UQo and Ro 68-3400 that had previously been identiﬁed
as potent inhibitors of the mPTP [54]. Co-immunoprecipitation and
GST-CyP-D pulldown experiments conﬁrmed that CyP-D binds to
the PiC in a CsA-sensitive fashion and that binding is increased by
oxidative stress and to a lesser extent CAT that sensitise mPTP
opening to [Ca2+] [53]. Furthermore we were able to demonstrate a
close correlation between the ability of both ubiquinone analogues
and N-ethylmaleimide to inhibit mPTP opening and phosphate
transport into mitochondria [53]. Additional support for an
important role for the PiC in mPTP opening comes from the recent
observation that phosphate is required for inhibition of mPTP
opening by CsA or CyP-D knockdown [55]. There is also circum-
stantial evidence to support such a role. Thus the knockdown of the
PiC in HeLa cells reduces their sensitivity to apoptosis induced by
staurosporine [56], conditions under which the mPTP mediates
apoptosis [57], whilst PiC over-expression can induce apoptosis [56].
2.1.4. Other proteins
Several other proteins have been proposed to be components of
the mPTP, including the voltage activated anion channel (VDAC, also
known as porin) and the peripheral benzodiazepine receptor (see
[13,58,59]). However, the evidence for their involvement has been
largely circumstantial [24,28]. Of these proteins the one for which the
evidence was considered strongest is VDAC. Thus Crompton et al.
reported that GST-CyP-D pulled down both VDAC and ANT from
solubilised heart mitochondria [46], although in our own experiments
using solubilised liver mitochondrial membranes only VDAC was
bound [45]. Evidence was also presented implicating VDAC1 in the
binding of ubiquinone analogues that inhibit the mPTP such as UQ0
and Ro 68-3400 [54,60,61]. However, it was later demonstrated that
mitochondria lacking VDAC1 were still inhibited by these compounds
[62] and that mitochondria lacking all three isoforms of VDAC showed
normal mPTP opening [63]. These data eliminate VDAC as an essential
component of the mPTP.
2.2. A proposed model for the mPTP
The data summarised above led us to propose a model for the
mPTP that is summarised in Fig. 1. It is suggested that the some of the
ANT and PiC may form a heterodimer in the inner mitochondrial
membrane for which there is some evidence from electron micro-
scopy studies of “the ATP synthasome” [64,65]. When triggered by
elevated matrix [Ca2+] [25,27,40], one or both of these membrane
transporters will undergo a conformation change facilitated by the
peptidyl-prolyl cis–trans isomerase activity of CyP-D that is inhibited
by the binding of adenine nucleotides to the ANT and activated by
oxidative stress. It should be noted that the triggering by calcium
does not necessarily require an increase in matrix [Ca2+] but may be
the consequence of an increase in oxidative stress that sensitises the
mPTP to the prevailing [Ca2+] [29,40]. Indeed, this is likely to be the
critical mechanism that operates during reperfusion [66] as will be
discussed further in Section 3.2 ‘Conditions during ischaemia and
reperfusion favour mPTP opening’ [67]. Interestingly, Krämer et al.
have demonstrated that the PiC of yeast mitochondria can be
converted into a non-speciﬁc anion channel by dithiol cross-linking
between two Cys28 residues within trans-membrane helix 1 to form
a PiC dimer [68] and there is an equivalent cysteine residue (Cys27) in
mammalian PiC. This could be the site of action of HgCl2 that
converts the mammalian PiC into a unidirectional transporter with
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the observed binding of the PiC to the PAO-column that is CAT-
insensitive. If so, then it is likely that the PiC forms the pore of the
mPTP whilst the conformation of the associated ANT plays more of a
regulatory role [53]. When interacting with the ANT in the “c”
conformation or with no adenine nucleotide bound it is proposed
that the PiC is more sensitive to the conformational change that
induces pore formation. By contrast, when associated with the ANT
in the “m” conformation the PiC would undergo the conformation
change less readily. This could explain the ability to demonstrate
pore opening in mitochondria containing no ANT1 or ANT2, but with
reduced sensitivity to calcium and no sensitivity to ligands of the
ANT [51]. Oxidative stress and PAO may activate mPTP opening both
by inhibiting adenine nucleotide binding to the ANT and by
enhancing CyP-D binding to the PiC. Ubiquinone analogues and
NEM are proposed to inhibit mPTP opening by both enhancing the
“m” conformation of the ANT and by binding to the PiC to inhibit its
conformational change into a pore.
3. mPTP opening is a critical factor in reperfusion injury and
heart failure
3.1. Ischaemia and reperfusion injury deﬁned (reviewed in [16,70–73])
During a myocardial infarction or cardiac surgery the heart, or
portions of it, may become totally deprived of blood (ischaemia). A
myocardial infarction is caused by a clot forming in one of the
coronary arteries supplying the left ventricle with oxygen and
respiratory fuels. This is known as a coronary thrombosis and
produces an area of ischaemia that corresponds to that part of the
ventricle exclusively supplied by the blocked artery. Ischaemia also
occurs during surgical procedures such as in valve replacement and
some coronary artery bypass graft operations where blood ﬂow
through the coronary arteries must be prevented. In both cases, if the
blood ﬂow is absent for long enough, the ischaemic tissue will die of
necrosis and so if the heart is to be salvaged, the blood ﬂow must be
restored as soon as possible. However, the very act of reperfusion can
exacerbate the damage to the heart that occurred during ischaemia.
This phenomenon is called “reperfusion injury” and is characterised
by an area of cell death, known as the infarct, the size of which reﬂects
both the area supplied by the coronary artery(ies) whose blood ﬂow
was blocked and the time of ischaemia. The majority of the cell death
is necrotic and is accompanied by release of intracellular enzyme such
as lactate dehydrogenase and Troponin I that together with infarct
size, can be used as an indicator of the extent of damage. Necrotic cell
death attracts neutrophils to the damaged area producing an
inﬂammatory response that exacerbates damage to the heart. Around
the periphery of the infarct there may be a smaller area of apoptotic
cell death that is not inﬂammatory [74,75]. In order to optimise the
recovery of the heart following a coronary thrombosis or cardiac
surgery it is important to minimise reperfusion injury, and for this to
be achieved it is important to understand the cause(s) of the damage.
As we describe below (Section 3.2 ‘Conditions during ischaemia and
reperfusion favour mPTP opening’), the conditions that prevail during
the initial stages of reperfusion are exactly those required for mPTP
opening suggesting that this may be a critical factor in determining
the extent of damage and recovery. Subsequent sections conﬁrm that
this is the case.
3.2. Conditions during ischaemia and reperfusion favour mPTP opening
During ischaemia and reperfusion the metabolism and ionic
homeostasis of the heart are profoundly perturbed in a way that
greatly favours mPTP opening as described below. These changes are
reviewed elsewhere [16,70–73] but are summarised below and
schematically in Fig. 2.3.2.1. Ischaemia
During ischaemia mitochondria in the myocytes that are
deprived of oxygen can no longer make ATP by oxidative
phosphorylation and this leads to a rapid fall in tissue [ATP] with
a concomitant rise in [ADP], [AMP] and [Pi]. These changes stimulate
glycolysis through activation of phosphofructokinase but this is
unable to provide sufﬁcient ATP to fuel the beating heart and
contraction rapidly ceases. Glycolysis continues to provide some ATP,
but as lactic acid accumulates the intracellular pH drops progres-
sively inhibiting phosphofructokinase and activating the Na+/H+
antiporter. The Na+ that enters via this route would normally be
pumped out again by the Na+/K+ ATPase but the greatly reduced
[ATP] inhibits this efﬂux leading to a progressive rise in intracellular
[Na+]. This in turn causes [Ca2+] to rise because the Na+/Ca2+
antiporter that usually pumps Ca2+ out of the cell, is inhibited or
reversed. In addition to the impaired ionic homeostasis, the decrease
in [ATP] leads to a large increase in [AMP] through the action of
adenylate kinase, and some of this AMP is converted into adenosine
and then inosine and xanthine through a purine degradation
pathway. These nucleosides leak out of the cell (and may have
vasodilator effects through purinergic receptors) and lead to a
gradual depletion of total adenine nucleotide. This may contribute to
the reversible impairment of haemodynamic function (known as
stunning) seen following a short period of ischaemia. Perhaps more
seriously, if sufﬁcient residual oxygen is available, xanthine may be
further oxidised by xanthine oxidase. This enzyme produces super-
oxide that can be further metabolised to other damaging reactive
oxygen species (ROS), particularly hydrogen peroxide by superoxide
dismutase and hydroxyl radicals through the Fenton reaction [76].
Heart cells actually contain xanthine dehydrogenase that is con-
verted into xanthine oxidase during ischaemia/reperfusion by the
oxidation of enzyme thiols and Ca2+-activated proteases. Since the
formation xanthine oxidase activity during ischaemia is very species
dependent and does not correlate with reperfusion injury [16,77,78]
its importance is unclear. However, this does not rule out a key role
for ROS formation in ischaemia since there are additional potential
sources of ROS. These include the respiratory chain, nitric oxide
synthase and NADPH oxidase [76,79]. Indeed, direct measurement of
ROS using dihydroethidium ﬂuorescence in the perfused heart
shows that there is a signiﬁcant increase in ROS as ischaemia
progresses and that this is a good indicator of the extent of damage
that will occur on reperfusion [80,81]. It is well established that ROS
production can increase under conditions of very low oxygen, in
response to the highly reduced state of the mitochondrial NADH that
favours superoxide production [82]. This increase in ROS is reﬂected
in an increased protein carbonylation of mitochondria isolated at the
end of ischaemia [83] that correlates with an increased calcium-
sensitivity of the mPTP opening [83–85].
In isolated myocytes ﬂuorescent measurements of [Ca2+]m suggest
that the amount of damage on reoxygenation also correlates with
[Ca2+]m at the end of reperfusion [86,87] and similar rises in [Ca2+]m
can be observed in the whole ischaemic heart [88]. Furthermore,
attenuation of mitochondrial calcium overload with ruthenium red can
protect hearts from reperfusion injury [89]. Since increased [Ca2+]m
triggers opening of the mPTP under conditions of oxidative stress,
adenine nucleotide depletion and elevated [Pi], the changes in the
intracellular milieu during ischaemia might be predicted to open the
mPTP. However, this appears not to be the case since opening of the
mPTP is strongly inhibited at pH values below 7, probably by protons
competingwith Ca2+ at the trigger site [25,90]. Thus at the low pH after
prolonged ischaemia (b6.5) the mPTP is likely to remain closed and
direct measurements conﬁrm this (see Section 3.3 ‘Demonstration that
mPTP opening occurs during reperfusion but not ischaemia’ below).
Nevertheless, the depletion of ATP and elevated [Ca2+] that occurs in
ischaemia will lead to a gradual decline in cellular integrity as
degradative enzymes such phospholipases (PLA2) [91] and calcium-
Fig. 2. Schematic representation of the effects of ischaemia and reperfusion on heart cells that lead to mPTP opening and the development of an infarct. Changes occurring primarily
during ischaemia are indicated with solid lines and those during reperfusion with a dashed line. Where both lines are shown changes are initiated in ischaemia and continued or
accentuated in reperfusion. Not shown on the diagram is the possible translocation of Bax to themitochondria during ischaemia that may provide an additional means of cytochrome
c release. Note that where the effects of reperfusion are not sufﬁcient to induce substantial mPTP opening the heart will initially show impaired contraction (stunning) as a result of
the free radical damage and adenine nucleotide loss, but will eventually recover fully. Further details are given in Section 3 ‘mPTP opening is a critical factor in reperfusion injury and
heart failure’ of the text.
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ATP-dependent repair processes are inhibited by the lack of ATP.
There may also be some BAX translocation to the mitochondria
leading to permeabilisation of the outer membrane and cytochrome c
release [93]. This has the potential to initiate apoptosis but only if ATP
levels are maintained sufﬁciently to drive this energy dependent form
of cell death [13]. If the tissue remains ischaemic for prolonged
periods, damage to the cell will lead to rupture of the sarcolemma and
necrotic cell death. However, shorter periods of ischaemia are
tolerated and the heart recovers on reperfusion. It may show impaired
function initially (stunning) but given sufﬁcient time it will recover
[70,71,94–96]. A major factor that determines the extent of damage
upon reperfusion of the ischaemic heart appears to be the extent to
which the mPTP opens at reperfusion as described below.
3.2.2. Reperfusion
At reperfusion additional factors come into play on top of the
increased [Ca2+], [Pi], oxidative stress and adenine nucleotidedepletion that the myocytes experience during ischaemia. These
are an additional burst of ROS production, further calcium overload
of the mitochondria and the return of the intracellular pH from the
acidic values present in ischaemia. The return of oxygen allows a
resumption of respiration and hence mitochondrial energisation and
ATP production. The increased mitochondrial membrane potential
stimulates the uptake into the matrix of any Ca2+ that has
accumulated in the cytosol during ischaemia [86,88,97] whilst the
presence of oxygen induces an additional burst of ROS production
[66,76,80,81]. The source of the ROS is debated but involves
molecular oxygen interacting with a reduced electron carrier to
produce superoxide. The rate of such superoxide production is very
sensitive to [O2] [82] which explains the burst of ROS seen upon
reoxygenation as the returning oxygen meets a highly reduced
respiratory chain. Some ROS may come from the activity of xanthine
oxidase but probably the majority are formed by the mitochondrial
respiratory chain. A major site of superoxide production is complex 1
which is stimulated by a high NADH/NAD ratio such as may occur at
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Additional matrix superoxide production may occur at the CoQ
binding site on complex 1 that receives electrons from the N2 FeS
centre, at succinate dehydrogenase (complex 2) and complex 3
[82,98,99]. There are also pathways for ROS elimination including
superoxide dismutase (SOD) to convert O2U− into H2O2 which is then
removed by glutathione peroxidase or catalase [79,99]. However, at
reperfusion these defence mechanisms may become overwhelmed
leading to oxidative stress as ROS accumulate. In addition to their
direct effects on the mPTP, ROS have additional effects that indirectly
inﬂuence mitochondrial function and mPTP opening. Thus ROS can
oxidise iron sulphur proteins in complex 1, complex 3 and aconitase,
and they can also cause thiol oxidation and inhibition of the ATPase
and adenine nucleotide translocase. In addition, they lead to
oxidation of glutathione that may then form mixed disulphides
with proteins, including inner membrane proteins, that modulate
their activity [100]. Such protein modiﬁcation is also thought to have
inhibitory effects on ion pumps and therefore exacerbate the effects
of ATP deprivation on ionic homeostasis [101–103]. Another effect of
ROS is to cause peroxidation of the unsaturated fatty acid
components of the phospholipids, and especially cardiolipin of the
inner mitochondrial membrane, which leads to further inhibition of
respiratory chain activity [104,105]. Furthermore, lipid peroxidation
causes the release of reactive aldehydes such as 4-hydroxynonenal
that can modify membrane proteins including the ANT [106] and
might explain the cardioprotective effects of over-expressing mito-
chondrial aldehyde dehydrogenase [107].
An additional player during reperfusion is nitric oxide (NO). This
may increase during ischaemia and can have either a protective or
damaging role during reperfusion, depending on its concentration and
the prevailing conditions [76,108,109]. At low concentrations it can
exert a protective role that is mediated through a signalling pathway
involving cyclic GMP formation as discussed below (Section 4.4 ‘Pre-
conditioning and post-conditioning protect heart from reperfusion
injury by inhibiting the mPTP’). NO will also inhibit cytochrome
oxidase competitively with respect to oxygen [110] and this could
exert a protective role by reducing the mitochondrial membrane
potential, leading to less mitochondrial calcium accumulation.
However, inhibition of cytochrome oxidase will also cause redox
centres of the respiratory chain to become more reduced and this has
the potential to enhance superoxide production [82]. Not only can this
induce oxidative stress in its own right, but the superoxide may also
react with NO to produce peroxynitrite that exerts its own effects on
mitochondria. Peroxynitrite modiﬁes mitochondrial proteins, includ-
ing the ANT and components of the respiratory chain leading to an
inhibition of oxidative phosphorylation and activation of the mPTP
[111–115].
Although the increased ROS, peroxynitrite and [Ca2+] at reperfu-
sion have the potential to cause mPTP opening on their own
they are insufﬁcient if the intracellular pH remains low [90,116].
However, reperfusion also allows the intracellular pH to return to
normal over a period of 2–3 min as lactic acid leaves the cell and other
pH regulatory transporters are active such as the Na+/H+ antiporter
and bicarbonate-linked pH regulatory transporters [117,118]. It is at
this point that the pore has been shown to open (see Section 3.3
‘Demonstration that mPTP opening occurs during reperfusion but not
ischaemia’), and this corresponds with the peak release of intracel-
lular lactate dehydrogenase and the heart going into a hypercon-
tracted state [34,116]. The initial damage in the ﬁrst few minutes of
reperfusion may be relatively modest, but the size of the infarct
increases over several hours of reperfusion [95,96] and protection
from reperfusion injury can be mediated by pharmacological inter-
ventionwithin the ﬁrst 15min of reperfusion [73]. This suggests that it
may not only be the initial opening of the mPTP that is important for
reperfusion injury but in addition a progressive opening that is
transmitted from mitochondria to mitochondria and myocyte tomyocyte. Such a phenomenon could be explained by “ROS-induced
ROS release” whereby opening of the mPTP itself produces ROS that
leads to a cascade of further mPTP opening [85,119,120], although
others have proposed an alternative mechanism involving the
activation of an inner membrane anion channel by ROS-mediated
glutathione oxidation [121–123].
The cause of mPTP induced ROS production is not certain but may
involve outer membrane rupture leading to cytochrome c release. This
may directly affect ROS production since oxidised intermembrane
cytochrome c has the potential to be reduced by superoxide, thus
regenerating oxygen and reduced cytochrome c that can be re-
oxidised by complex 4 [124]. Loss of cytochrome c may prevent this
superoxide scavenging and hence lead to ROS accumulation. Alter-
natively, cytochrome c release may cause caspase activation and
subsequent cleavage of the p75 subunit of complex 1 to enhance
superoxide production at this site [125,126]. Even if the mPTP opens
initially, but then closes again, as we have shown can occur during
reperfusion [116], myocytes may still be susceptible to death by
apoptosis if mitochondria swell sufﬁciently to rupture the outer
membrane, and release cytochrome c and other apoptotic factors
[13,19,127]. In reperfusion injury, apoptotic death may only be
relevant to the cells surrounding the necrotic core of the infarct
[74,75], but in the failing hypertrophic heart apoptosis may be more
signiﬁcant [128], althoughmore recent data suggests that here too the
majority of death may be necrotic [129] (and see Section 5 ‘Heart
failure in cardiac hypertrophy may be ameliorated by inhibition of the
mPTP’). Overall, it is thought that the combined effects of ROS,
elevated [Ca2+] and possibly peroxynitrite play a decisive role in the
transition from reversible to irreversible reperfusion injury, and that it
is the opening of the mPTP that represents the critical point in
committing the myocyte to cell death [13,15,16,73,130].
3.3. Demonstration that mPTP opening occurs during reperfusion but
not ischaemia
In order to demonstrate directly that the predicted mPTP opening
does occur at reperfusion, techniques have been developed that can
measure mPTP opening in situ. In isolated cardiac myocytes subjected
to simulated ischaemia and reperfusion, mPTP opening can be
monitored using ﬂuorescence microscopy to measure the mitochon-
drial membrane potential with a ﬂuorescent dye such as tetra-
methylrhodamine methyl ester (TMRM) as a surrogate indicator of
mPTP opening [131,132]. Conﬁrmation that any depolarisation
observed is due to mPTP opening is achieved by demonstrating the
ability of CsA, sometimes supplemented with triﬂuoperazine, to
inhibit the process [133]. A more sophisticated approach is simulta-
neously to determine the distribution of another ﬂuorescent dye,
calcein (green ﬂuorescence), that can only cross the inner mitochon-
drial membrane when the pore opens [134,135]. This technique has
been applied successfully to cardiac myocytes subject to oxidative
stress and simulated ischaemia/reperfusionwhere the data conﬁrmed
that the mPTP remains closed during ischaemia but opens upon
reperfusion as the pH returns to normal. The data also suggested that
the most critical factor inﬂuencing the extent of mPTP opening is the
degree of oxidative stress rather than calcium overload [136–140].
Indeed there is increasing evidence that it is the increase of ROS
during ischaemia that primes the mPTP for opening at reperfusion
[81,85,141–143].
In order to determine the extent of mPTP opening in the perfused
heart subject to ischaemia/reperfusion, two alternative techniques
have been developed. DiLisa et al. determined the loss of mitochon-
drial NAD+ that accompanies reperfusion as a surrogate indicator of
pore opening [144]. This was inhibited by CsA, conﬁrming that it
involvedmPTP opening, althoughwith this technique it is not possible
eliminate the possibility that some of the CsA-sensitive NAD+ loss
represents disruption of mitochondria during their isolation rather
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opening in situ, devised in this laboratory, measures the mitochon-
drial entrapment of [3H]-2-deoxyglucose (DOG) as an indicator of
pore opening [145]. In this “Hot-DOG” technique, hearts are ﬁrst
loaded with [3H]-DOG which is phosphorylated within the cytosol to
the dead-end metabolite, DOG-6-phosphate. This can only enter the
mitochondria when the mPTP opens. Thus when mitochondria are
rapidly isolated in the presence of EGTA to reseal the mPTP, the
amount of [3H]-DOG entrapped within the mitochondria gives an
indication of the extent of pore opening. However, if the pores open
and then close again the [3H]-DOG will remain entrapped. To
determine the extent to which such resealing occurs, a comparison
can be made between mitochondrial [3H]-DOG entrapment of hearts
loaded before (pre-loading) and after (post-loading) ischaemia/
reperfusion [116]. Using the “Hot-DOG” technique we were able to
conﬁrm that the mPTP does not open during ischaemia, but rather
occurs after the ﬁrst 2–3 min of reperfusion when the intracellular
pH normalises [145,146]. Some of the pores that open initially at the
start of reperfusion where shown to close again as reperfusion
progressed [116].
In this laboratory we have also used the “Hot-DOG” to conﬁrm less
mPTP opening is associated with cardioprotection induced by CsA and
SfA [34], the free radical-scavenging anaesthetic propofol [147],
pyruvate [116], urocortin [142] and ischaemic pre-conditioning [84],
thus providing further evidence for the critical role of mPTP opening
in reperfusion injury. Other laboratories have used the technique to
demonstrate that protection induced by pharmacological blockade ofFig. 3. Proposed sites of action of cardioprotective protocols Proposed sites of action of cardio
the mPTP during ischaemia (solid lines) and lead to its opening at reperfusion as shown in
Section 4 ‘Inhibition of the mPTP protects hearts against ischaemia reperfusion injury’ are ind
or decrease in the change of the parameter shown. No attempt is made to incorporate into th
brief discussion of these pathways is given in Section 4.4 ‘Pre-conditioning and post-cond
detailed account the reader is referred elsewhere [205–207].the sodium/proton antiporter (NHE1) [148–150] or short-term
physical training [151] is also associated with less mPTP opening.
4. Inhibition of the mPTP protects hearts against ischaemia
reperfusion injury
Inhibition of mPTP opening in situ with resulting protection
against reperfusion injury can be achieved using a variety of strategies.
These are described below and summarised in Fig. 3.
4.1. Targeting CyP-D
CsA was initially shown to protect isolated cardiac myocytes from
reoxygenation injury [152] and we subsequently showed protection
from reperfusion injury in the Langendorff perfused heart [153]. Since
then many laboratories have conﬁrmed these data using both global
and regional models of ischaemia and reperfusionwith determination
of injury using enzyme release, infarct size and haemodynamic
function [154–156]. Furthermore, genetic ablation of CyP-D also
provides potent protection against ischaemia reperfusion injury of
the heart [37,38] and brain [39] with CyP-D knockout mice showing a
substantial decrease in infarct size. Thus targeting the mPTP has
proven potential as a pharmacological target for the reduction of
reperfusion injury following stroke, coronary thrombosis and heart
surgery. However, the use of CsA in cardioprotection is not ideal
because of its tight binding to cytosolic cyclophilin-A and resulting
inhibition of the calcium sensitive protein phosphatase, calcineurin,protective protocols. This scheme provides an outline of the major factors that sensitise
Fig. 2. The proposed sites of action of cardioprotective agents or protocols described in
icated with grey boxes and solid arrows. Circles containing+ or− indicated an increase
e diagram the signalling pathways involved in pre-conditioning or post-conditioning. A
itioning protect heart from reperfusion injury by inhibiting the mPTP’, but for a more
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immunosuppressive activity [158]. To circumvent these problems CsA
analogues or SfA can be employed that are inactive against calcineurin
but bind tightly to CyP-D, and inhibit mPTP opening. Such drugs are at
least as cardioprotective as CsA [34,145,156,159] and importantly, are
effective even when added only during early reperfusion. Thus CsA
and SfA can reduce the infarct size of hearts inwhich a coronary artery
is occluded and then re-opened to mimic the clinical treatment of a
coronary thrombosis [154,155]. This has led us to propose that the
initial opening of the mPTP is followed by “ROS-induced ROS release”
(see above – Section 3.3 ‘Demonstration that mPTP opening occurs
during reperfusion but not ischaemia’) that may be responsible for the
increase in infarct size with time [85,119,120]. Inﬂammation through
neutrophil recruitment and activation may be an additional cause of
this progressive increase in infarct size [73]. Recently, in an in vivo
mouse model allowing 24 h and 30 days reperfusion following 25 min
regional ischaemia, the CsA analogues Debio-025 given at reperfusion
was found to give substantial protection [159]. This is encouraging for
future clinical practice in the treatment of coronary thrombosis with
thrombolysis or percutaneous coronary intervention (PCI). Indeed,
protection by CsA against mPTP opening has been reported in human
heart cells subject to simulated ischaemia/reperfusion injury [160]
and the ﬁrst small clinical trials do conﬁrm improved recovery
following CsA treatment of patients undergoing PCI treatment
following a coronary thrombosis [161].
4.2. Targeting other components of the mPTP
Opening of the mPTP is not totally dependent on CyP-D and even
when CyP-D is ablated genetically or fully inhibited with CsA the
permeability transition can be induced with a higher calcium load or
oxidative stress [36,40]. Thus targeting another component of the
mPTP would be an attractive strategy for cardioprotection. The mPTP
can be inhibited by targeting the ANT with BKA and this can protect
cells from mPTP-induced cell death in some systems [13,44]. Clearly
this is not an appropriate strategy for cardioprotection since the ANT is
vital for the generation of cytosolic ATP via oxidative phosphorylation
to energise the contractile cycle [44]. Targeting the phosphate carrier
is also unlikely to be effective for similar reasons and we have found
ubiquinone analogues to be damaging to the heart rather than
cardioprotective [13]. Thus, at present, targeting CyP-D with non-
immunosuppressive CsA derivatives is the best available strategy, but
it remains possible that other targets that affect the mPTP may be
found. However there are very effective indirect ways of inhibiting the
mPTP that have shown potent cardioprotective effects.
4.3. Indirect strategies for inhibiting the mPTP
Cardioprotection is provided by free radical scavengers such as the
anaesthetic propofol which can directly inhibit mPTP opening in
isolated mitochondria [162,163] and mitochondria from propofol
treated hearts [147]. Furthermore, we have demonstrated inhibition of
the mPTP by propofol in the intact heart using the “Hot-DOG”
technique [147] and conﬁrmed that propofol is protective in an in vivo
pig model of cardiopulmonary bypass with warm blood cardioplegia
that closely matches current clinical practice [164]. Other anaesthetics
such as isoﬂurane and desﬂurane have also been shown to offer
protection that is associated with less ROS formation and calcium
overload [165–169]. ROS-scavengers such as MitoQ that are speciﬁ-
cally targeted to mitochondria through a positively-charged hydro-
phobic moiety [170] may be especially promising and have already
been shown to protect against reperfusion injury in the Langendorff
perfused rat heart model [171]. Inhibition of the Na+/H+ exchanger
with amiloride derivatives such as cariporide is also known to protect
the heart from reperfusion injury [172]. These drugs are assumed to
act by preventing sodium and therefore calcium overload duringischaemia whilst maintaining low pH during reperfusion[173]. Here
too the “Hot-DOG” technique has conﬁrmed inhibition of mPTP
opening in situ [148–150].
Pyruvate is one of the most protective agents against reperfusion
injury which probably works by acting as a free radical scavenger that
also maintains a low intracellular pH and is an excellent respiratory
substrate to replenish ATP during reperfusion [116,174]. Again, direct
measurement of mPTP opening with the “Hot-DOG” technique has
conﬁrmed that pyruvate reduces mPTP opening at reperfusion and
also causes those pores that open initially to close again [116].
Protection of hearts from reperfusion injury can also be achieved by
reducing cytosolic and mitochondrial calcium overload with antago-
nists of plasma membrane or mitochondrial calcium channels such as
verapamil and ruthenium red [175–182]. It would seem probable that
this involves inhibition of the mPTP although this has not been
demonstrated directly. A similar mechanism probably applies to the
protection seen with elevated extracellular [Mg2+] (N8 mM) during
the reperfusion phase [183–185]. Protection from reperfusion injury
by trimetazidine, an “anti-ischaemic” drug used for the treatment of
heart failure has also been shown to reduce mPTP opening [186].
Although the mechanism is unclear it is likely to be secondary to its
metabolic effect of switching the heart from oxidising fatty acids
(which produce more ROS) to carbohydrates [187].
4.4. Pre-conditioning and post-conditioning protect heart from
reperfusion injury by inhibiting the mPTP
Avery effective way of protecting the heart from reperfusion injury
is “ischaemic pre-conditioning” (IP) whereby the heart is subject to one
or more brief ischaemic episodes with recovery before the prolonged
period of ischaemia. This procedure induces two phases of protection;
an immediate effect and a “second window” that occurs 24–48 h later
[188,189]. The latter probably involves upregulation of a range of
protective proteins including heat shock proteins, cell survival
proteins and enzymes involved in protection against oxidative stress,
perhaps through a mechanism activated by free radicals and stress-
activated protein kinases [189,190]. Protection can also be induced
when very brief (10 s) intermittent ischaemic periods are included
within the ﬁrst fewminutes of reperfusion, a protocol known as “post-
conditioning” [191,192] which has obvious clinical potential in the
treatment of coronary thrombosis by angioplasty [193].
The exact mechanisms involved in ﬁrst window of pre-condition-
ing and post-conditioning are still debated but in both cases there is
strong evidence that mPTP inhibition is involved [85,194]. Direct and
indirect techniques have been used to conﬁrm this. We have used the
“Hot-DOG” technique to demonstrate directly that IP not only reduces
the opening of themPTP during the early phase of reperfusion but also
increased subsequent pore closure [84]. Indeed, there is a good
correlation between reduced pore opening and cardioprotection.
Indirect measurements have led to similar conclusions. Thus several
other studies have shown that mitochondria isolated from IP hearts
following ischaemia or reperfusion are less sensitive to calcium-
induced mPTP opening than mitochondria from control hearts but
that this effect is not seen immediately after the IP protocol
[83,84,141,195,196]. These data suggest that the protective effect of
IP on mitochondria somehow develops during the ischaemia and
reperfusion phases.
Our own data have suggested that the mechanism for this
involves the mitochondria from IP hearts experiencing less oxidative
stress during ischaemia and reperfusion than those from control
hearts [141,196]. Indeed we and others have shown that three other
pre-conditioning protocols, treatment with urocortin [142], apomor-
phine [197] or exposure to several intermittent brief hypothermic
episodes prior to index ischaemia (temperature pre-conditioning)
[141] are also associated with mitochondria that develop less
oxidative stress during ischaemia and reperfusion and are less
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isolated cardiac myocytes have revealed that IP desensitises the
mitochondria to pore opening induced by oxidative stress [139,198]
and experiments performed with two-photon microscopy in the
perfused heart have yielded similar data [199]. Thus it seems
probable that IP may increase the ability of mitochondria to scavenge
ROS, perhaps coupled with a decrease in ROS production, although
the mechanisms involved remain unclear [85]. Post-conditioning is
also thought to involve desensitisation of the mPTP to calcium-
induced opening since mitochondria isolated from such hearts during
reperfusion are less sensitive to mPTP opening than those isolated
from control hearts [200].
Taking all the data together, the emerging picture is that
ischaemic pre-conditioning protects the heart by reducing oxidative
stress during ischaemia and reperfusion and that this leads to less
mPTP opening. There may also be additional effects of IP on
mitochondrial calcium loading since IP has been reported to reduce
the detrimental effects of ischaemia on sarcoplasmic Ca2+ release
and uptake leading to decreased Ca2+ overload during ischaemia and
reperfusion [201–204].
What is less clear is the signalling pathways involved in mediating
the effects of pre-conditioning and post-conditioning. Both post-
conditioning and the numerous pre-conditioning stimuli probably
recruit common signalling pathways to inhibit mPTP opening,
although there is no universal consensus as to what these pathways
are or how they interact. However, there is strong evidence for the
activation of protein kinase Cɛ (PKCɛ) by ROS and/or other factors
(e.g. adenosine, bradykinin, noradrenaline) released during the pre-
conditioning protocol. Others have implicated NO and protein kinase
G, perhaps via activation of mitochondrial KATP (mitoKATP) channels,
and the Akt/glycogen synthase kinase 3β (GSK3β) pathway and we
have recently reviewed this evidence [85]. Reviews expressing
alternative views can be found elsewhere [205–207].
Our own data on pre-conditioning [141,142,196] can be sum-
marised as follows. We ﬁnd no evidence that the IP-mediated
inhibition of mPTP opening at reperfusion involves translocation of
protein kinases or connexin 43 to the mitochondria or direct
phosphorylation of mitochondrial proteins. Rather our data suggest
that the key factor causing inhibition of mPTP opening by different
pre-conditioning stimuli is a reduction in the oxidative stress
experienced by mitochondria during prolonged ischaemia and
reperfusion. This causes less oxidation of the critical thiol groups on
the mPTP responsible for sensitising mPTP opening to [Ca2+] [40,48].
Themechanisms bywhich ROS levels are decreased in IP hearts during
prolonged ischaemia and reperfusion remain to be elucidated but
probably involve activation of protein kinase Cɛ (PKCɛ), either via
receptor-mediated events or through transient increases in ROS
during the IP protocol. Other signalling pathways may show cross-
talk with this primary mechanism, but we can ﬁnd no evidence for a
role for mitoKATP channels [85]. Indeed, we are sceptical about the
conclusions reached in many experiments performed with openers
and blockers of this channel since they can have many non-speciﬁc
effects on mitochondrial function [85,208,209]. Our own data and our
review of the literature also lead us to conclude that protection by pre-
conditioning occurs in two phases: ﬁrst, prevention of mPTP opening
at the initial phase of reperfusion; second, through a continuing
protection during reperfusion by preventing a cascade of mPTP-
induced ROS production with further mPTP opening. This latter phase
of protection may involve an increase in ROS removal or reduction in
mitochondrial ROS production caused by Akt-mediated GSK3-β
inhibition. In this context it is signiﬁcant that pharmacological
inhibition of GSK3-β during reperfusion has been shown to be
cardioprotective [210].
A plausible mechanism for these effects is as follows. It is well
established that mPTP opening causes mitochondrial swelling,
rupture of the outer membrane [211] release of cytochrome c andcaspase activation [20]. In addition, the pro-apoptotic factor Bax can
translocate to mitochondria during ischaemia [93] and this, in
conjunction with cleaved Bid (tBid), might cause cytochrome c
release during prolonged ischaemia [212] despite there being no
evidence of mPTP opening [145,199]. The resulting loss of
cytochrome c will slow electron transfer out of complex 3 and
thus potentially cause increased ROS production from either
complex 3 or complex 1. Indeed such increased ROS production
has been shown to occur follow cytochrome c loss during apoptosis
[213]. Increased ROS production during ischaemia and reperfusion
may also occur through caspase 3 mediated cleavage of the p75
component of complex 1[125,126]. Protection from the rise in ROS
that accompanies such cytochrome c release could be mediated by
survival kinase cascades (e.g. Akt and GSK3-β) in two ways. They
might stimulate ROS removal as described above for the ischaemic
phase or they could reduce the Bax-induced cytochrome c release.
Indeed, it is well established that survival kinases can block
apoptosis by inhibiting cytochrome c release [214]. This is brought
about by Akt-mediated phosphorylation of the pro-apoptotic Bcl-2
family member Bad [215,216] and, via GSK3β phosphorylation and
inactivation, the stabilisation of the anti-apoptotic Bcl-2 family
member Mcl-1 [217].
5. Heart failure in cardiac hypertrophy may be ameliorated by
inhibition of the mPTP
Congestive heart failure may develop following cardiac infarction
or in chronic hypertension (high blood pressure) as the heart
undergoes compensatory hypertrophy to restore some measure of
cardiac output. However, over time this progresses into a decom-
pensated state including dilation and decreased function. This is
associated with a gradual death of normal cardiac myocytes with a
proliferation of ﬁbroblasts leading to a disorganised enlarged heart
that fails to pump efﬁciently [218–220]. There is evidence that
dysregulation of calcium handling may occur under such conditions,
with a reduction in peak systolic [Ca2+] but an elevation and
prolongation in diastolic [Ca2+]. This will result in reduced systolic
contraction and a delay in diastolic relaxation [218,219]. The
perturbation of normal calcium handling may also be a critical factor
in the development of cardiac hypertrophy since it has been shown
that a similar phenotype can be induced in transgenic mice with
enhanced sarcolemmal L-type Ca2+ channel activity. When accom-
panied by acute stimulation of β-adrenergic receptors that led to
further enhancement of Ca2+ inﬂux, hearts of these mice showed
progressive myocyte necrosis that caused pump dysfunction and
premature death of the mice [129].
It has been proposed that such calcium overload might act via
calcineurin mediated upregulation of gene expression to induce the
hypertrophic phenotype. Indeed pharmacological or genetic down-
regulation of calcineurin activity reduces hypertrophy in mouse
models [220–222] whilst calcineurin over-expression induces hyper-
trophy [223]. Interestingly, the heart mitochondria from such mice
showed impaired respiratory chain activity and increased ROS
production. Taken together these data suggest that the dysregulation
of calcium handling in cardiac hypertrophy might also lead to
mitochondrial calcium overload and ROS production that together
would favour enhanced mPTP opening and provide an explanation for
the observed death of myocytes. In support of this hypothesis, it was
shown recently that the development of progressive myocyte cell
death and heart failure in the transgenic model described above was
not apparent in mice lacking CyP-D [129]. Thus it seems possible that
pharmacological targeting of the mPTP may be beneﬁcial for
preventing or slowing the progression of congestive heart failure.
Indeed, such inhibition of mPTP opening may provide an additional
mode of action of the “anti-ischaemic” drug trimetazidine, which is
used for the treatment of heart failure and switches the fuel
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support of this trimetazidine has been shown to reducemPTP opening
in a rabbit model of reperfusion injury [186]. Interestingly, the use of
CyP-D knockout mice is also providing evidence for a critical role of
the mPTP in other chronic diseases associated with skeletal muscle
dysfunction. Thus in some muscular dystrophies changes in the
disposition of the sarcolemma leads to calcium overload with
resulting necrotic damage that is not seen in CyP-D knockout mice
or following treatment with CsA and Debio-025 (a CsA analogue
inactive against calcineurin) [224,225].
6. Conclusion
In recent years it has become apparent that mitochondria have two
distinct persona, akin to Dr. Jeckyll and Mr. Hyde. In the former state
they act to supply the voracious appetite of the beating heart for ATP,
with increased matrix calcium providing the link between the greater
ATP demand at higher work rates with higher rates of respiration and
oxidative phosphorylation. However, when the heart is overloaded
with calcium, especially when this is accompanied by oxidative stress,
the mPTP opens and the mitochondria embrace their darker side, and
precipitate death of the myocytes. This happens acutely in reperfusion
injury and chronically in congestive heart failure. Inhibition of mPTP
opening by either genetic or pharmacological inhibition of CyP-D
provides protection from both pathologies in animal models,
conﬁrming the mPTP as a promising drug target in human
cardiovascular disease. Indeed, the ﬁrst clinical trials have shown
promising results and conﬁrm improved recovery following CsA
treatment of patients undergoing PCI treatment following a coronary
thrombosis [161]. However, CyP-D is not an ideal target because even
when it is ablated genetically, or is fully inhibited with CsA, the
permeability transition can be induced with a higher calcium load or
oxidative stress [36,40]. There are also potential problems associated
with CsA and its analogues, since even those such as Debio-25 that do
not inhibit calcineurin do bind to other cyclophilins and inhibit their
peptidyl-prolyl cis–trans isomerase activity [226]. Thus there remains
a scope for the development of better drugs that target another
component of the mPTP without interfering with the normal function
of the mitochondria. These might have the potential to be used
prophylactically in those patients at risk of ischaemic heart disease.
For this to be achieved it will be important to establish the true
molecular composition of the mPTP and the mechanism and
regulation of its opening. This continues to be an on going focus of
research in our laboratory.
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